70 pages matching patients pts in this book
Results 1-3 of 70
What people are saying - Write a review
We haven't found any reviews in the usual places.
determined normal levels We used survival analysis with timedependent overall clinical response rate was 58 1 the overall pathological response
HER2 expression end efficacy of dosedense anthracyclinecontaining adju
9 other sections not shown
activity administered adverse events analysis anthracycline antibody antitumor apoptosis assessed Background baseline biopsy breast cancer breast cancer patients Cancer Center Cancer Institute capecitabine carboplatin carcinoma clinical trial cohort colorectal cancer combination Conclusions correlated cycles diarrhea docetaxel dose level doxorubicin drug effects efficacy EGFR enrolled erlotinib evaluated expression follow-up G-CSF gefitinib gemcitabine gene Germany glioma grade HER2 Hospital Imatinib infusion inhibition inhibitor irinotecan liver median age metastatic metastatic breast cancer Methods months neoadjuvant neutropenia observed Oncology oral overall survival oxaliplatin paclitaxel patients pts patients received patients with advanced pharmacokinetic phase II study phase II trial plasma Poster Discussion Poster Session primary prior progression protein pts received randomized range receptor recurrence regimen respectively response rate Results rituximab significant solid tumors stable disease stage surgery tamoxifen taxane therapy tolerated toxicity trastuzumab treated treatment tumor tumor cells University vaccine VEGF vinorelbine weeks women